Cabaletta Bio, Inc. (CABA) is entering a catalyst-rich period as it advances Rese-cel, its lead autologous CD19-CAR T cell therapy, across multiple autoimmune diseases while preparing for a potential first Biologics License Application submission in 2027.
Autoimmune disorders such as systemic lupus erythematosus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are driven by pathogenic B cells that produce harmful autoantibodies.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com